Premium
Plasma C3c changes in myasthenia gravis patients receiving high‐dose intravenous immunoglobulin during crisis
Author(s) -
Kamolvarin N.,
Hemachudha T.,
Ongpipattanakul B.,
Phanuphak P.,
Viddayakorn P.,
Sueblinvong T.
Publication year - 1989
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1989.tb03887.x
Subject(s) - myasthenia gravis , antibody , complement system , medicine , complement (music) , immunoglobulin g , immunology , gastroenterology , endocrinology , chemistry , biochemistry , complementation , gene , phenotype
— Fast‐migrating C3c, a sensitive index of complement activation, was assayed in the plasma of 2 myasthenia gravis (MG) patients in crisis who received high‐dose IV immunoglobulin therapy. Dramatic responses were observed in both patients. Clinical improvement paralleled a decrement in C3c levels, suggesting that regulation of complement activation may be one possible mechanism of IV immunoglobulin treatment in MG.